Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
Work
Year: 2014
Type: article
Abstract: Current treatment modalities can cure up to 70–80 % of patients with classical Hodgkin lymphoma. Approximately, 20–30 % of patients require further treatment options. Brentuximab vedotin has been appr... more
Source: Annals of Hematology
Institutions Istanbul University, Antalya IVF, Cukurova University, Hacettepe University, Turkish Armed Forces +6 more
Cites: 10
Cited by: 30
Related to: 10
FWCI: 3.878
Citation percentile (by year/subfield): 77.81
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: hybrid
APC paid (est): $4,390